

Prior Authorization Request Form Fax Back To: (866) 940-7328 Phone: (800) 310-6826

## **Specialty Medication Prior Authorization Cover Sheet**

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <a href="https://www.uhcprovider.com">www.uhcprovider.com</a> for medication fax request forms.)

Patient Information					
Patient's Name:					
Insurance ID:	Date of Birth:	Height: Weight:			
Address:		Apartment #:			
City:	State:	Zip Code:			
Phone Number:	Alternate Phone:	Sex: ☐ Male ☐ Fem	ale		
Provider Information					
Provider's Name:	Provider ID Number:				
Address:	City:	State: Zip Code:			
Suite Number:	Building Number:				
Phone Number:	Fax number:				
Provider's Specialty:					
Medication Information					
Medication:	Quantity:	ICD10 Code:			
Directions:	Diagnosis:	Refills:			
Physician Signature**:		Initial here if DAW:			
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.					
Medication Instructions					
Medication Instructions  Has the patient been instructed on how to Self-A	Administer?	☐ Yes ☐ No			
	Administer?	☐ Yes ☐ No			
Has the patient been instructed on how to Self-					
Has the patient been instructed on how to Self- Is this medication a New Start?	Initiation Date: / /	☐ Yes ☐ No			
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reserved:  **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No  Date of Last Dose: / /  ☐ Yes ☐ No  pport stated diagnosis.	n(s)		
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical research any pertinent clinical informational clinical information may be needed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No  Date of Last Dose: / /  ☐ Yes ☐ No  pport stated diagnosis.	n(s)		
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reserved:  **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patient ian Signature" above and comformation"	☐ Yes ☐ No  Date of Last Dose: / /  ☐ Yes ☐ No  pport stated diagnosis. s plan, including medication  plete	n(s)		
Has the patient been instructed on how to Self-Alls this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reservity the self-Alls and pertinent clinical informational clinical information may be needed previously tried and failed.  Delivery Instructions  Note: Delivery coordination requires a "Physical "Provider Information" and "Patient Information" and "Patient Information" and "Patient Information"	Initiation Date: / / sponse to current therapy? Ation that would pertain to sued depending on your patient ian Signature" above and comformation" ided free of charge to the patient	☐ Yes ☐ No  Date of Last Dose: / / ☐ Yes ☐ No  pport stated diagnosis. s plan, including medication  plete  at at the time of delivery	n(s)		



## Inlyta - Washington

## PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Inform	lation						
First Name:		Last Name:			Member ID:		
Address:							
City:		State:			ZIP Code:		
Phone:		DOB:			Allergies:		
Primary Insurance Information:				1			
Is the requested medication □ New or □ Continuation of Therapy? If continuation, list start date:							
Is this patient currently hos	spitalized?	Yes □ No	If recently discha	rged, list discha	arge date:		
Section B - Provider Inform	nation						
First Name:			Last Name:			M.D./D.O.	
Address:			City:		State:	ZIP code:	
Phone:	Fax:		NPI #:	,	Specialty:		
Office Contact Name / Fax a	ttention to:						
Section C - Medical Inform Medication:	ation				Strength:		
Directions for use:					Quantity:		
Diagnosis (Please be specif	fic & provide as	much info	rmation as possible)	:	ICD-10 COD	DE:	
Is this member pregnant?   Yes   No If yes, what is this member's due date?							
		If yes	s, what is this mem	ber's due date?			
Section D – Previous Medications	cation Trials	If yes	s, what is this mem	ber's due date?  Dates of Ther	apy Reaso	on for failure /	
Section D - Previous Medic	cation Trials				apy Reaso	on for failure /	
Section D - Previous Medic	cation Trials				apy Reaso		
Section D - Previous Medic	cation Trials				apy Reaso		
Section D - Previous Medic	cation Trials				apy Reaso		
Section D – Previous Medications	Stre	ngth	Directions	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	
Section D – Previous Medications  Medications  Section E – Additional inform	Stre	ngth	Directions  of why preferred m	Dates of Ther	rapy Reaso	continuation	



## Inlyta - Washington

PRIOR AUTHORIZATION REQUEST FORM

**Date:** \_\_\_\_\_

Member Firs	t name:	Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	Does the patient have one of the following diagnoses? (If yes, check which applies)  □ Renal cell cancer						
	□ Thyroid carcinoma						
	Is the medication being requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?						
□ Yes □ No	If yes, list supported use:						
	RENAL CELL CANCER						
□ Yes □ No Has the patient's disease relapsed?							
□ Yes □ No	Does the patient have a medically or surgically unresectable tumor?						
□ Yes □ No	□ Yes □ No Does the patient have a diagnosis of Stage IV disease?						
		THYROID CARCING	DMA				
	Does the patient have one of the following diagnoses? (If yes, check which applies)						
	<ul><li>□ Follicular carcinoma</li><li>□ Hürthle cell carcinoma</li></ul>						
	□ Papillary carcinoma						
	-	y of the following? (If yes,	check which applies)				
□ Yes □ No	Unresectable Recurrent Disease						
☐ Persistent Locoregional Disease☐ Metastatic Disease☐							
□ Vos □ No	Is the patient's disease refractory to radioactive iodine treatment? (If yes, complete Section D above)						
CONTINUATION OF THERAPY							
□ Yes □ No Does the patient show evidence of progressive disease while on Inlyta therapy?							
2.00 2.10	•	<u> </u>	Il response to Inlyta therapy?				
Wa a M	If yes, list positive respons	•	a response to myta therapy:				
□ Yes □ No	□ Yes □ No						

**Confidentiality Notice:** This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.

Physician Signature: